Tumor-associated antigen presented on MHC class I molecule and Tumor-associated antigen presented on MHC class II molecule (TAA-MHC I and TAA-MHC II)

Tumor-associated antigens presented on MHC class I and II molecules represent peptides derived from proteins aberrantly or preferentially expressed by tumor cells and displayed at the cell surface bound to major histocompatibility complex (MHC) molecules. MHC class I–restricted antigens, recognized by CD8+ cytotoxic T lymphocytes (CTLs), can mediate direct tumor cell killing, while MHC class II–restricted antigens, recognized by CD4+ T helper cells, contribute to antitumor immunity through immune activation and coordination[1][2][3]. MHC class I and II antigen presentation by tumor cells is central to tumor immunosurveillance and underpins many immunotherapeutics, including checkpoint inhibitors and cancer vaccines. However, tumors can evade immune detection by downregulating components of the MHC pathway, acquiring defects in antigen processing, or undergoing selection for antigen-loss variants, which constitute important mechanisms of therapy resistance and immune evasion[2][3]. The definition “tumor-associated antigens presented on MHC Class I and II molecules” is broad and refers to a category rather than a specific canonical target; precision immunotherapies typically focus on defined antigens (e.g., MART-1, NY-ESO-1, MAGE-A3, etc.) complexed with a specific HLA allele[1][2].

Other names

Tumor-associated antigens (TAAs)cancer-associated antigensMHC-presented tumor antigens

Drugs and therapeutic approaches act by enhancing T cell recognition of tumor-associated antigen–MHC complexes, reversing immune evasion, or boosting antigen presentation for immune-mediated tumor killing[2][3][4].